SC
ALNY icon

Steph & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

Steph & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-135
Closed -$44.7K – 286
2026
Q1 		$44.7K Hold
135
– – 0.01% 205
2025
Q4 		$53.7K Sell
135
-50
-27% -$22.1K 0.02% 177
2025
Q3 		$84.4K Hold
185
– – 0.03% 155
2025
Q2 		$60.3K Buy
+185
New +$51.2K 0.02% 172

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steph & Co's ALNY Position: Q2 2026 in Review

Steph & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 135 shares — an estimated $44.7K sold.

Steph & Co first reported a position in ALNY in Q2 2025 and held it in 4 quarters. The position peaked at $84.4K in Q3 2025. 784 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Steph & Co reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Steph & Co sold 135 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $44.7K.
  • Steph & Co first reported a position in Alnylam Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Steph & Co's Alnylam Pharmaceuticals position peaked at $84.4K in Q3 2025.
  • 784 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Steph & Co's 13F filing for Q2 2026, filed 16 Jul 2026.